Osteal Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing innovative combination product therapeutics for musculoskeletal infections and their complications. With its lead investigational candidate, VT-X7, receiving multiple designations from the US FDA, including Breakthrough Therapy and Orphan Disease, the company is on track to complete its clinical trial program for Periprosthetic Joint Infection (PJI) and anticipates a product launch in 2025. Osteal is committed to expanding its pipeline with additional therapeutic candidates, positioning itself for rapid and sustained growth in the biopharmaceutical sector.